Published in Cancer Weekly, July 20th, 2004
Specific terms of the deal were not disclosed.
Immusol will utilize Affymetrix GeneChip technology to identify distinct oncology pathways from its engineered tumor cells in biological assays. These modified cancer cells were developed at Immusol by specific down-regulation of tumor suppressors or oncogenes. Using GeneChip brand technology, expression of associated, affected genes will be analyzed and compared.
The program aims to elucidate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.